Mobilizing Our Resources to Find Solutions for COVID-19

We are committed to:

Mobilizing efforts at the Janssen Pharmaceutical Companies of Johnson & Johnson to develop a vaccine candidate against COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2 (also known as 2019-nCoV)

Collaborating with regulators, healthcare organizations, institutions and communities worldwide to help ensure our research platforms, existing science and outbreak expertise can be maximized to stem this public health threat

Collaborating with other partners to screen a library of antiviral molecules, with the aim to identify potential treatments for rigorous research and development

Commitment to Pandemic Preparedness

We are committed to global pandemic preparedness across multiple disease areas, developing new vaccines and treatments to combat a wide range of infectious diseases that are already pandemics, such as HIV, hepatitis B and tuberculosis (TB), or that have pandemic potential, including Ebola, Zika and Influenza.

About Our Vaccine Program

We will leverage our AdVac® and PER.C6® technologies, which provide the ability to rapidly upscale production of the optimal vaccine candidate.

These technologies were used to develop and manufacture Janssen’s investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo and Rwanda, and were also used to construct the Company’s Zika, RSV and HIV vaccine candidates.

Joint Venture with Fosun

On February 11, 2020, J&J announced an agreement with Fosun Pharma to establish a joint venture to advance the development and potential commercialization of a COVID-19 vaccine candidate.

In March 2020, J&J, Fosun Pharma and the Indian government announced that they would join forces to build a COVID-19 vaccine manufacturing facility in India to support the global vaccine supply chain.

We have a long-standing commitment to establish and emerging epidemics and will continue to mobilize resources to support global efforts in combating the current coronavirus outbreak.

Paul Stoffels, M.D.
Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson

About the Virus

COVID-19 is announced as the official name of the disease caused by novel coronavirus. The virus is named SARS-CoV-2.

The virus is classified as belonging to the large family of coronaviruses (CoVs).

December 31, 2019
China alerted the World Health Organization (WHO) to several cases of pneumonia in Wuhan. The virus is unknown.

January 7, 2020
WHO announces they have identified a novel coronavirus. It is from the CoV family, which includes SARS and the common cold.

February 26, 2020
The first case of COVID-19 was reported in South America, marking the spread of the disease to six of seven continents.

March 11, 2020
WHO declares the COVID-19 outbreak a pandemic.

March 30, 2020
J&J announces that a lead vaccine candidate has been selected to move into trials. BARDA and J&J commit $1B to vaccine R&D.

J&J pledges to supply one billion vaccines worldwide for emergency pandemic use.

We are collaborating with other partners to screen a library of antiviral molecules, with the aim to identify potential treatments for rigorous research and development.

This is not the first time that a member of the large family of coronaviruses (CoVs) has led to an outbreak of infections among humans. The crises involving severe acute respiratory syndrome (SARS) in China in 2003 and Middle East respiratory syndrome (MERS) in 2012 were both caused by CoVs.

January 12, 2020
J&J initiates vaccine development and collaborates with others to screen a library of antiviral molecules.

January 30, 2020
WHO declares the COVID-19 outbreak a public health emergency of international concern (PHEIC).

Collaborating with other partners to screen a library of antiviral molecules, with the aim to identify potential treatments for rigorous research and development.

What We Know

This is not the first time that a member of the large family of coronaviruses (CoVs) has led to an outbreak of infections among humans. The crises involving severe acute respiratory syndrome (SARS) in China in 2003 and Middle East respiratory syndrome (MERS) in 2012 were both caused by CoVs.

J&J is mobilizing resources to find solutions for COVID-19.

This is not the first time that a member of the large family of coronaviruses (CoVs) has led to an outbreak of infections among humans. The crises involving severe acute respiratory syndrome (SARS) in China in 2003 and Middle East respiratory syndrome (MERS) in 2012 were both caused by CoVs.

J&J is mobilizing resources to find solutions for COVID-19.

This is not the first time that a member of the large family of coronaviruses (CoVs) has led to an outbreak of infections among humans. The crises involving severe acute respiratory syndrome (SARS) in China in 2003 and Middle East respiratory syndrome (MERS) in 2012 were both caused by CoVs.

J&J is mobilizing resources to find solutions for COVID-19.

This is not the first time that a member of the large family of coronaviruses (CoVs) has led to an outbreak of infections among humans. The crises involving severe acute respiratory syndrome (SARS) in China in 2003 and Middle East respiratory syndrome (MERS) in 2012 were both caused by CoVs.

J&J is mobilizing resources to find solutions for COVID-19.

This is not the first time that a member of the large family of coronaviruses (CoVs) has led to an outbreak of infections among humans. The crises involving severe acute respiratory syndrome (SARS) in China in 2003 and Middle East respiratory syndrome (MERS) in 2012 were both caused by CoVs.